One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 767-769

  Brown, Daniel B ^a   Gonsalves, Carin F ^a   Yeo, Charles J ^b   Witkiewicz, Agnes K ^b   Carr, Brian I ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemoembolization; Gemcitabine; Pancreatic carcinoma

Indexed keywords

ANTIEMETIC AGENT; CA 19-9 ANTIGEN; CISPLATIN; DIURETIC AGENT; GEMCITABINE; SODIUM THIOSULFATE; STEROID;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER SURVIVAL; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEPATIC ARTERY; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; LIVER METASTASIS; LYMPHADENECTOMY; MALE; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PANCREAS RESECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SIGNET RING CARCINOMA; SPLENECTOMY; TUMOR VOLUME;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DEOXYCYTIDINE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77956325761     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000919     Document Type: Article

References (9)

1. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778-3785, 2009.
2. Allison DC, Piantadosi S, Hruban RH, et al: DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 67: 151-159, 1998.
3. Brown DB, Geschwind JF, Soulen MC, Millward SF and Sacks D: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 20: 317-323, 2009.
4. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M and Kitano S: Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas 31: 69-73, 2005.
5. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Bang S, Jeon TJ, Kim MH, et al: Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Pancreatology 6: 635-641, 2006. (Pubitemid 46360715)
7. Furuse J, Maru Y, Yoshino M, et al: Hepatic arterial infusion of 5-fluorouracil for liver metastases from pancreatic carcinoma: results from a pilot study. Hepatogastroenterology 48: 208-211, 2001.
8. Ishii H, Furuse J, Nagase M, et al: Hepatic arterial infusion of 5-fluorouracil and extrabeam radiotherapy for liver metastases from pancreatic carcinoma. Hepatogastroenterology 51: 1175-1178, 2004.
9. Fujii M, Miyake H, Sasaki K, Takagi T, Takamura K and Tashiro S: Arterial infusion chemotherapy for the patient of unresectable pancreatic carcinoma with multiple liver metastases: a case report. J Med Invest 50: 199-202, 2003. (Pubitemid 38019769)